Feed Category: Biotech Index

Orchard Therapeutics (Europe) LimitedBOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss… [Read More]

(Bloomberg) — Harpoon Ventures, whose investors include Andreessen Horowitz veteran Peter Levine and former Olympic swimmer Michael Phelps, has raised a $125 million fund to… [Read More]

Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd.New… [Read More]

Immutep LimitedMedia ReleaseSYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel… [Read More]

By David Bautz, PhDNASDAQ:KMDAREAD THE FULL KMDA RESEARCH REPORTBusiness UpdateOn December 6, 2023, Kamada Ltd. (NASDAQ:KMDA) announced the execution of a binding memorandum of understanding… [Read More]

ImmunoGen, Inc. IMGN announced that the FDA accepted its supplemental biologics license application (“sBLA”), seeking to convert the accelerated approval for its sole marketed drug,… [Read More]

Company targets first quarter 2024 for trial initiationPotential to be first orally-administered TNF-α inhibitor treatment for RABALTIMORE, December 06, 2023–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD)… [Read More]

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost… [Read More]

Investors might want to bet on Harpoon Therapeutics, Inc. (HARP), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward… [Read More]

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 5th:PDD Holdings Inc. PDD: This company which provides… [Read More]

iBio, Inc.BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its… [Read More]

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints… [Read More]